#China #Shanghai #Dizal #Golidocitinib #Birelentinib

Dizal's Clinical Innovations to Be Highlighted at ASH 2026

As the medical community prepares for one of the most significant events in hematology, the 68th American Society of Hematology (ASH) Annual Meeting, Dizal Pharmaceutical is set to make a notable impression. Scheduled for December 2026, Dizal will present the latest advancements from its hematological disease portfolio through three oral sessions and five poster presentations, showcasing a commitment to enhancing treatment modalities in oncology and related fields.

Showcasing the Latest Findings

Dizal’s presentations are expected to focus on two key compounds: Golidocitinib and Birelentinib. The former is notably recognized as the world's first Janus kinase 1 (JAK1) inhibitor authorized for treating relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). In its investigative studies, Golidocitinib demonstrated remarkable efficacy with a high overall response rate (ORR) of 44.3%, including an impressive complete response rate (CRR) of 23.9% among patients. This trial will be particularly significant as updated findings regarding Golidocitinib's application in patients with secondary hemophagocytic lymphohistiocytosis (HLH) will be presented, extending prior work showcased at the European Hematology Association Congress earlier in 2026.

Key Presentation:

• - Title: Golidocitinib Monotherapy for Adult Hemophagocytic Lymphohistiocytosis
• - Lead Author: Prof. Zhao Wang
• - Timing: 10:30 AM – 10:45 AM CST, Dec 13, 2026

In another highlight, Birelentinib is an innovative dual inhibitor designed to inhibit both Lyn and Bruton’s tyrosine kinase (BTK) pathways. This drug has shown particularly promising results in both monotherapy and its combination with venetoclax in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data indicate that Birelentinib not only can provide durable responses but also maintains an acceptable safety profile across various patient demographics.

Featured Birelentinib Presentations:

• - Title 1: Phase II Study of Birelentinib in Treatment-Naïve Patients with CLL/SLL
• - Timing: 2:45 PM – 3:00 PM CST, Dec 12, 2026
• - Title 2: Combination of Birelentinib and Venetoclax for Treatment-Naïve Patients
• - Lead Author: Prof. Ting Niu
• - Timing: 2:45 PM – 3:00 PM CST, Dec 12, 2026

Key Takeaways from Dizal's Commitment

Dizal's CEO, Dr. Xiaolin Zhang, expressed strong optimism regarding the portfolio's capability to offer next-generation therapies to patients worldwide. The breadth of studies at ASH 2026 reflects significant advancements in managing T-cell and B-cell lymphomas, in addition to autoimmune disorders, suggesting a brighter future for patient care in these often challenging conditions.

The findings from Dizal’s clinical studies are poised to contribute substantially to the ongoing discourse around hematological treatments at the ASH meeting. As innovative therapeutics like Golidocitinib and Birelentinib gain exposure, they have the potential to shift paradigms in the treatment strategies for complex hematological diseases, ultimately striving towards improved patient outcomes.

Dizal's portfolio embodies the future of hematological treatment, offering hope for patients and laying down new avenues for research and therapy in oncology. The community eagerly anticipates these insights, aiming to harness them for better health solutions on a global scale.

For more information about Dizal's presentations and innovative pipeline, visit their official site or follow them on LinkedIn and X.